Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKCA Akcea Therapeutics	$18.17	$18.16	$8.00 ▼ $21.70	$1.85B	1.45	361,806 shs	N/A
ALDR Alder Biopharmaceuticals	$18.88	$18.88	$8.39 ▼ $19.12	$1.58B	2.64	5.12 million shs	N/A
CORT Corcept Therapeutics	$70.86 -3.1%	$72.75	$32.33 ▼ $117.33	$7.51B	0.15	1.19 million shs	563,090 shs
IGMS IGM Biosciences	$1.28 +0.8%	$1.25	$0.92 ▼ $22.50	$76.51M	0.48	378,434 shs	292,245 shs
ZYME Zymeworks	$14.25 -1.6%	$12.46	$9.03 ▼ $17.70	$992.98M	1.19	577,775 shs	431,049 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKCA Akcea Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ALDR Alder Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CORT Corcept Therapeutics	0.00%	-1.42%	-0.53%	+13.85%	+113.18%
IGMS IGM Biosciences	0.00%	-5.88%	+9.40%	+4.92%	-89.25%
ZYME Zymeworks	0.00%	+6.82%	+12.83%	+23.59%	+40.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALDR Alder Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	4.8278 of 5 stars	3.5	3.0	0.0	4.3	2.9	4.2	1.9
IGMS IGM Biosciences	4.4842 of 5 stars	3.0	5.0	0.0	4.6	2.0	3.3	0.6
ZYME Zymeworks	3.1605 of 5 stars	3.5	4.0	0.0	0.0	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKCA Akcea Therapeutics	0.00	N/A	N/A	N/A
ALDR Alder Biopharmaceuticals	0.00	N/A	N/A	N/A
CORT Corcept Therapeutics	3.00	Buy	$138.25	95.10% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	329.69% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	47.37% Upside

Current Analyst Ratings Breakdown

Latest ALDR, AKCA, IGMS, ZYME, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/6/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$135.00
5/6/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKCA Akcea Therapeutics	$488.54M	3.78	$0.51 per share	35.54	$5.78 per share	3.14
ALDR Alder Biopharmaceuticals	$1.62M	977.10	N/A	N/A	$1.61 per share	11.73
CORT Corcept Therapeutics	$675.04M	11.13	$1.24 per share	57.05	$6.49 per share	10.92
IGMS IGM Biosciences	$2.68M	28.55	N/A	N/A	$0.82 per share	1.56
ZYME Zymeworks	$93.38M	10.63	N/A	N/A	$6.63 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKCA Akcea Therapeutics	$40.77M	$0.48	N/A	N/A	N/A	-12.34%	-8.94%	-8.02%	N/A
ALDR Alder Biopharmaceuticals	-$296.43M	-$4.87	N/A	N/A	N/A	N/A	-226.13%	-66.86%	N/A
CORT Corcept Therapeutics	$141.21M	$1.16	61.09	38.30	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
IGMS IGM Biosciences	-$195.79M	-$3.27	N/A	N/A	N/A	-7,417.79%	-317.97%	-71.43%	8/13/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.49	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	7/30/2025 (Estimated)

Latest ALDR, AKCA, IGMS, ZYME, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IGMS IGM Biosciences	-$0.12	N/A	N/A	N/A	$0.40 million	N/A
8/7/2025	N/A	ZYME Zymeworks	-$0.52	N/A	N/A	N/A	$17.18 million	N/A
8/4/2025	Q2 2025	CORT Corcept Therapeutics	$0.23	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKCA Akcea Therapeutics	N/A	N/A	N/A	N/A	N/A
ALDR Alder Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKCA Akcea Therapeutics	N/A	12.17	11.78
ALDR Alder Biopharmaceuticals	1.74	8.94	8.94
CORT Corcept Therapeutics	N/A	3.07	2.96
IGMS IGM Biosciences	N/A	5.71	5.71
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKCA Akcea Therapeutics	19.27%
ALDR Alder Biopharmaceuticals	N/A
CORT Corcept Therapeutics	93.61%
IGMS IGM Biosciences	42.79%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
AKCA Akcea Therapeutics	1.50%
ALDR Alder Biopharmaceuticals	15.40%
CORT Corcept Therapeutics	20.80%
IGMS IGM Biosciences	57.00%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKCA Akcea Therapeutics	248	101.60 million	N/A	Optionable
ALDR Alder Biopharmaceuticals	202	83.84 million	N/A	Optionable
CORT Corcept Therapeutics	300	106.04 million	83.99 million	Optionable
IGMS IGM Biosciences	190	59.78 million	25.70 million	Optionable
ZYME Zymeworks	460	69.68 million	67.56 million	Optionable

ALDR, AKCA, IGMS, ZYME, and CORT Headlines

Recent News About These Companies

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Average Price Target from Analysts

July 19 at 2:29 AM | americanbankingnews.com

Zymeworks (NYSE:ZYME) Trading 7% Higher - Should You Buy?

July 18 at 6:15 PM | marketbeat.com

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

July 18 at 11:00 AM | zacks.com

Zymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025

July 17 at 6:36 AM | quiverquant.comQ

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17 at 6:36 AM | financialpost.comF

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17 at 6:36 AM | financialpost.comF

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 16, 2025 | marketbeat.com

ZYME | Zymeworks Inc. Annual Cash Flow Statement | MarketWatch

July 11, 2025 | marketwatch.com

Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

July 9, 2025 | finance.yahoo.com

Zymeworks (NYSE:ZYME) Given "Neutral" Rating at HC Wainwright

July 3, 2025 | marketbeat.com

Zymeworks Amends Warrant Agreement with EcoR1 Capital

June 27, 2025 | tipranks.com

ZYME - Zymeworks Inc Registered Shs Dividends - Morningstar

June 27, 2025 | morningstar.comM

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

June 25, 2025 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

June 20, 2025 | zacks.com

Rhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

June 20, 2025 | marketbeat.com

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500

June 18, 2025 | kalkinemedia.comK

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

June 12, 2025 | seekingalpha.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

June 4, 2025 | zacks.com

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

June 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDR, AKCA, IGMS, ZYME, and CORT Company Descriptions

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Alder Biopharmaceuticals NASDAQ:ALDR

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Corcept Therapeutics NASDAQ:CORT

$70.86 -2.24 (-3.06%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$71.66 +0.80 (+1.12%)

As of 07/18/2025 06:22 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

IGM Biosciences NASDAQ:IGMS

$1.28 +0.01 (+0.79%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.28 0.00 (0.00%)

As of 07/18/2025 06:09 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Zymeworks NYSE:ZYME

$14.25 -0.23 (-1.59%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.26 +0.01 (+0.04%)

As of 07/18/2025 05:23 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time